Back To Top

You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
Why register? Save your profile, save trials, and enter treatment history for more accurate matching.
1

Targeted Therapy Before Surgery for HER2 Positive Breast Cancer Guided by ctDNA Blood Tests

EUREKA Study: Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer Using ctDNA and HARPS Biomarker Assay

Purpose: To study the effects of using a personalized treatment approach based on a tumor biomarker test (HARPS) and blood monitoring (ctDNA) in HER2 positive breast cancer.

Who is this for?: People with stage I or stage II or stage III HER2 positive (HER2+) breast cancer that is larger than 2 cm or has spread to nearby lymph nodes. Must not have received prior chemotherapy, radiation, or hormone therapy or more than 1 cycle of HER2 targeted therapy, View full eligibility criteria

What's involved?


What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The HARPS biomarker test is a lab test done on your tumor tissue to see how active the HER2 signals are inside your cancer cells. It checks how strongly the cancer is using HER2 to grow, which can help doctors choose the most appropriate treatment.</li> <li class="seamTextUnorderedListItem">ctDNA stands for circulating tumor DNA. Researchers are using ctDNA blood monitoring to look for tiny pieces of cancer DNA that can be found in your bloodstream to help track how well treatment is working over time.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT07402473' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.lbbc.org/about-breast-cancer/types-breast-cancer/her2-positive' target='_blank'>Living Beyond Breast Cancer: HER2 positive or HER2 low breast cancer</a> </li></ul>
1

Targeted Therapy Before Surgery for HER2 Positive Breast Cancer Guided by ctDNA Blood Tests

EUREKA Study: Phase 2 Study to Optimize Neoadjuvant Therapy in HER2-positive Early-stage Breast Cancer Using ctDNA and HARPS Biomarker Assay
Icon

Nearest Location from 94107:
2537 miles
RWJBarnabas Health - Robert Wood Johnson University Hospital, Somerset
Somerville, NJ

Icon

Visits:
Every 3 weeks, up to 8 times

Icon

ClinicalTrials.gov: NCT07402473

Icon

Phase II